Renovo Concepts

Executive Summary

Renovo Concepts, Inc., headquartered in San Antonio, Texas, is a privately held medical device and drug delivery company founded in 2017. The company has developed a novel therapeutic modality aimed at mitigating the deleterious effects of secondary injury on soft tissues, addressing a critical unmet need in trauma and surgical care. By targeting the secondary injury cascade, Renovo's platform has the potential to improve healing outcomes and reduce complications such as chronic inflammation and fibrosis. While the company remains in early development stages without disclosed funding or valuation, its proprietary approach could differentiate it in the regenerative medicine space. The absence of public milestones suggests Renovo is currently focused on preclinical validation or initial clinical studies, with potential for forthcoming data releases to demonstrate proof of concept.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Data Release for Lead Modality60% success
• Q2 2027Series A Funding Round Announcement50% success
• Q1 2028First-in-Human Clinical Trial Initiation35% success